Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com -- Shares of Tevogen Bio Holdings Inc (NASDAQ:TVGN) soared 10.4% following the company’s reaffirmation of its top-line revenue forecast, projecting significant earnings in its oncology pipeline. The biotechnology firm expects to generate $1 billion in revenue in its launch year, with a cumulative five-year estimate ranging from $10 billion to $14 billion.
The optimism in Tevogen’s stock comes on the heels of an announcement made on April 28, 2025, where the company highlighted its business strategy aimed at achieving commercial success by ensuring patient accessibility to its products. The forecast is based on Tevogen’s unique approach to drug development, which it believes could serve as a sustainable model for medical innovation.
In addition to the revenue forecast, Tevogen has secured a deal with CD 8 Technology Services LLC, which will provide up to $50 million for the company’s dedicated research and development and manufacturing facility. This agreement is particularly noteworthy as it is structured to have no impact on shareholder equity.
Tevogen’s CEO, Ryan Saadi, MD, MPH, expressed confidence in the company’s intellectual property and U.S.-based cell therapy manufacturing capabilities. He indicated an eagerness to keep shareholders informed about the company’s forecasts and the valuation of its internal assets.
Supporting the positive market response, D. Boral (OTC:BOALY) Capital analyst Jason Kolbert provided a favorable outlook on Tevogen’s technology and its potential market reach. "Beyond infectious diseases, Tevogen’s platform technology holds promise for applications in solid tumors and autoimmune diseases, expanding its total addressable market. With key clinical readouts ahead, an emphasis on operational efficiency, and the potential for industry collaborations, Tevogen represents an emerging leader in next-generation T cell therapies," Kolbert said.
Investors appear to be responding to Tevogen’s strategic initiatives and the robust revenue forecast, which suggests a strong entry into the oncology market and continued growth over the next several years. As the company advances its platform technology and explores further applications, its stock movement today reflects a market that sees potential in Tevogen’s approach to revolutionizing T cell therapy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.